Market Size of Liraglutide Industry
| Study Period | 2018-2029 |
| Market Size (2024) | USD 3.40 Billion |
| Market Size (2029) | USD 4 Billion |
| CAGR (2024 - 2029) | 3.16 % |
| Fastest Growing Market | North America |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Liraglutide Market Analysis
The Liraglutide Market size is estimated at USD 3.40 billion in 2024, and is expected to reach USD 4 billion by 2029, growing at a CAGR of 3.16% during the forecast period (2024-2029).
The COVID-19 pandemic co-morbidities included hypertension, diabetes, cardiovascular disease, and cancer. According to an article,” 89-LB: COVID-19 Outcomes in Patients Who Started GLP1-RAs during Hospitalization,” published by the American Diabetes Association in June 2022, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were considered beneficial in improving COVID-19 outcomes due to their anti-inflammatory properties. Patients admitted for severe interstitial bilateral pneumonia in the COVID-19 ward due to SARS-COV2 infection and having type-2 diabetes or in-hospital hyperglycemia were treated with GLP-1 RAs in addition to standard therapy.
Furthermore, the Centers for Disease Control highlighted that COVID-19 was a serious public health threat for people with serious chronic diseases, including diabetes. People with diabetes were more likely to experience complications when infected with the virus. As per the American Diabetes Association, people with diabetes, if uncontrolled, had worse outcomes if infected with a virus such as COVID-19. The International Diabetes Federation explained that when people with diabetes develop a viral infection, it can be harder to treat due to fluctuations in blood glucose levels and diabetes complications as the immune system is compromised, making it harder to fight the virus and likely leading to a longer recovery period.
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type-2 diabetes and chronic obesity. It is used when diet and exercise alone do not result in good blood sugar control. It is a second-line therapy for diabetes, following first-line therapy with metformin. It is also used to help reduce the risk of heart and blood vessel problems, including heart attacks and strokes in patients with type-2 diabetes and established heart or blood vessel disease. Liraglutide is sold under the brand names Victoza and Saxenda.
The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for a substantial increase in access to insulin, the promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies. This important milestone provides a global mandate for diabetes efforts for the next decade.
Major factors that are expected to boost the growth of the studied market in the forecast period are rising obesity and inactivity rates among people, which have resulted in an increase in the diabetes population over time, a rise in the sedentary lifestyle, improper dietary patterns, and the inherent history of diabetes disorders. In addition, rising investment in research and development, technological developments, and new product launches will further provide potential opportunities for the growth of glucagon-like peptide 1 (GLP-1) agonists over the forecast period.
